Stryker Corporation $SYK is CWS Financial Advisors LLC’s Largest Position

CWS Financial Advisors LLC lessened its stake in shares of Stryker Corporation (NYSE:SYK) by 0.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 252,176 shares of the medical technology company’s stock after selling 1,974 shares during the quarter. Stryker makes up about 24.1% of CWS Financial Advisors LLC’s investment portfolio, making the stock its biggest position. CWS Financial Advisors LLC’s holdings in Stryker were worth $88,632,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. VanderPol Investments L.L.C. lifted its position in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after buying an additional 28 shares during the last quarter. Lantz Financial LLC lifted its position in shares of Stryker by 5.0% during the 3rd quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock worth $225,000 after buying an additional 29 shares during the last quarter. Stonebridge Capital Advisors LLC lifted its position in shares of Stryker by 0.4% during the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after buying an additional 29 shares during the last quarter. Tcfg Wealth Management LLC lifted its position in shares of Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after buying an additional 29 shares during the last quarter. Finally, Mechanics Financial Corp lifted its position in shares of Stryker by 1.2% during the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after buying an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $320.99 on Thursday. The firm’s fifty day simple moving average is $326.71 and its 200-day simple moving average is $350.36. The stock has a market capitalization of $123.06 billion, a price-to-earnings ratio of 37.15, a PEG ratio of 2.00 and a beta of 0.80. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Insider Buying and Selling at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on SYK. BTIG Research reduced their price objective on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research report on Friday, May 1st. JPMorgan Chase & Co. reduced their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Needham & Company LLC reduced their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Jefferies Financial Group restated a “buy” rating and set a $465.00 price objective on shares of Stryker in a research report on Wednesday, March 4th. Finally, Barclays cut their target price on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.